Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pivalyloxymethyl butyrate

Known as: Pivaloyloxymethyl butyrate, Pivaloyloxymethylbutyrate 
An acyloxyalkyl ester prodrug of butyric acid. Pivaloyloxymethylbutyrate inhibits histone deacetylase, resulting in cell differentiation, cell growth… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

AN-9Pivanex

Broader (1)

Butyrates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
Histone deacetylase inhibitory prodrugs that are metabolized to butyric acid and formaldehyde possess antineoplastic properties… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2007
2007
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
Histone modification has emerged as a promising approach to cancer therapy. We explored the in vivo efficacy of a butyric acid… Expand
2005
2005
Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells
A novel butyric acid derivative, pivaloyloxymethyl butyrate, AN-9, was previously shown to be a potent differentiating agent. AN… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Highly Cited
2004
Highly Cited
2004
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
This multicenter phase II trial evaluated the therapeutic activity and safety profile of pivaloyloxymethyl butyrate (Pivanex, AN… Expand
Review
2002
Review
2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), has demonstrated greater potency than BA… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2002
Highly Cited
2002
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
The novel prodrug of butyric acid, pivaloyloxymethyl butyrate (AN-9), a histone deacetylase inhibitor, shows great promise as an… Expand
Highly Cited
2001
Highly Cited
2001
Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
The interaction of Adriamycin and pivaloyloxymethyl butyrate (AN-9) was investigated in IMR-32 neuroblastoma and MCF-7 breast… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2000
2000
Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity.
Pivalyloxymethyl butyrate (AN9) is an anticancer derivative of butyric acid. In this study, doxorubicin (DXR) and AN9… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
1994
1994
Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL‐60 leukemic cell line
A butyric acid pro‐drug, pivaloyioxymethyl butyrate, AN‐9, developed in our laboratory, was previously shown to act as a… Expand
Highly Cited
1993
Highly Cited
1993
Rapid alteration of c‐myc and c‐jun expression in leukemic cells induced to differentiate by a butyric acid prodrug
The novel prodrug of butyric acid (BA), pivaloyloxymethyl butyrate, has been shown, in vitro, to induce differentiation and… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE